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Abstract 
Background: Chloroquine has been the treatment of choice for acute vivax malaria for more than 60 years. Malaria 
caused by Plasmodium vivax has recently shown resistance to chloroquine in some places. This study compared the 
efficacy and safety of fixed dose combination (FDC) of arterolane maleate and piperaquine phosphate (PQP) with 
chloroquine in the treatment of uncomplicated vivax malaria.
Methods: Patients aged 13–65 years with confirmed mono-infection of P. vivax along with fever or fever in the previ-
ous 48 h were included. The 317 eligible patients were randomly assigned to receive FDC of arterolane maleate and 
PQP (n = 159) or chloroquine (n = 158) for 3 days. Primaquine was given as an anti-relapse measure on day 3 and 
continued for 14 consecutive days. Primary efficacy analysis included assessment of the proportion of aparasitaemic 
and afebrile patients at 72 h. Safety endpoints were analysis of adverse events, vital signs, laboratory data, and abnor-
malities on electrocardiograph. Patients participated in the study for at least 42 days.
Results: In per protocol population, the proportion of aparasitaemic and afebrile patients at 72 h was 100 % 
(140/140) in the FDC of arterolane maleate and PQP group, and 99.3 % (145/146) in the chloroquine group (Fisher, 
p > 0.9999). In intent to treat population, the corresponding value was reported to be 96.9 % (154/159) in the FDC of 
arterolane maleate and PQP group and 98.7 % (156/158) in the chloroquine group (Fisher, p = 0.4479). The median 
parasite clearance time was 24 h in FDC of arterolane maleate and PQP group and 26 h in chloroquine group (Log-
rank, p = 0.2264). Similarly, median fever clearance time was 24 h in both the groups (Log-rank, p = 0.7750). In PP 
population, day 28 cure rates were 100 % in both the groups (95 % CI (96.52, 100.0 for FDC of arterolane maleate and 
PQP and 96.73, 100.0 in chloroquine group)). Incidence of adverse events was 82.4 % in the FDC of arterolane maleate 
and PQP group and 85.4 % in the chloroquine group. Most of the adverse events were mild to moderate in intensity. 
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Background
Plasmodium vivax, the second most important spe-
cies causing human malaria, accounts for about 40  % 
of malaria cases worldwide. It is prevalent in endemic 
areas in the Middle East, Asia, Oceania, Central and 
South America. In most areas where P. vivax is prevalent, 
malaria transmission rates are low, and the affected pop-
ulations, therefore, achieve little immunity to this para-
site. Consequently, people of all ages are at risk [1].
In India, chloroquine at a total dose of 25 mg base/kg 
body weight is the treatment of choice for vivax malaria, 
since P. vivax remains sensitive to chloroquine as shown 
by the therapeutic efficacy studies [2]. However, sporadic 
cases of resistance to chloroquine have been reported 
from India and other countries [3, 4]. In some countries, 
alternative regimen have been recommended for treat-
ment of vivax malaria [5]. In case there is an emergence 
of chloroquine resistance in vivax malaria, second-line, 
alternative anti-malarials should be available.
In some patients, P. vivax may cause relapse within a 
few weeks to a few months after initial infection [6]. For 
its prevention, primaquine should be given at a dose of 
0.25  mg/kg body weight daily for 14  days under super-
vision [7]. Primaquine is contra-indicated in known 
G6PD-deficient patients, infants and pregnant women 
[1, 7–9]. Caution should be exercised before administer-
ing primaquine in areas known to have high prevalence 
of G6PD deficiency [7]. Although chloroquine plus pri-
maquine is the first-line treatment for confirmed vivax 
malaria in most countries, emergence of chloroquine 
resistance has been reported from various parts of the 
world [1, 10, 11]. It is therefore becoming apparent that 
alternative treatment strategies should be investigated.
It is recommended by the WHO that in areas where 
artemisinin-based combination therapy (ACT), except 
artesunate plus sulfadoxine–pyrimethamine, has been 
adopted as the first-line treatment for falciparum malaria, 
it may also be used for vivax malaria. Also, in areas with 
chloroquine-resistant P. vivax, ACT (particularly those 
whose partner medicines have long half-lives) are recom-
mended for the treatment of vivax malaria [1].
Different artemisinin-based combinations (artemether–
lumefantrine, dihydroartemisinin–piperaquine, pyrona-
ridine artesunate, artesunate mefloquine) have been 
evaluated for the treatment of vivax malaria. A Cochrane 
review showed that dihydroartemisinin–piperaquine (RR 
0.32, 95 % CI 0.24–0.43; four trials, 1442 participants) and 
artesunate plus mefloquine (RR 0.30, 95 % CI 0.21–0.41; 
four trials, 1003 participants) were more effective than 
artemether–lumefantrine at reducing the incidence of 
P. vivax over 42 days’ follow-up [12]. A study conducted 
in Papua, Indonesia demonstrated that both dihydroar-
temisinin–piperaquine phosphate (DHA–PQP) and 
artemether–lumefantrine were tolerated and produced 
rapid clinical response in vivax malaria patients. However, 
DHA–PQP combination provided better post-treatment 
prophylaxis than artemether–lumefantrine, reducing P. 
vivax recurrences [13]. The efficacy of PQP has been eval-
uated in the treatment of vivax malaria. In a study of 280 
patients, a total dose of 1.5 g of PQP given over two days 
was compared with a combination of chloroquine base 
(1.2  g) and primaquine (30  mg). Both the regimens had 
equal efficacy in vivax malaria patients [14].
A completely synthetic ozonide anti-malarial based 
upon the 1,2,4-trioxolane pharmacophore was designed, 
optimized, developed, and named arterolane. Arterolane 
exhibits a rapid onset of action, potent activity against all 
erythrocytic stages of Plasmodium falciparum. Arter-
olane maleate is well absorbed with a tmax of 4.5–5.25 h. 
and has a relatively short t1/2 of 2–4 h. The plasma pro-
tein binding of arterolane is ~93 % [15]. A 33 % increase 
in systemic exposure to arterolane has been observed 
with food. Piperaquine is well absorbed following oral 
administration with maximum plasma piperaquine con-
centrations (Cmax) attained at 2.5–4.5 h (Tmax) post dose. 
The mean half-life ranged from 11 to 18 days   [16]. It is 
highly bound to plasma proteins (>99  %). Realizing the 
advantages, arterolane maleate and PQP are combined 
in a fixed-dose combination (FDC). The tolerability, effi-
cacy and pharmacokinetic profile of piperaquine makes it 
a promising partner drug for use with short and rapidly 
acting anti-malarial agents.
The commonly reported clinical adverse events in the FDC of arterolane maleate and PQP versus chloroquine group 
were vomiting (5.0 vs 5.1 %), headache (1.3 vs 3.2 %) and prolonged QT (1.9 vs 3.2 %). No deaths were reported. The 
pharmacokinetic analysis indicates that arterolane maleate is well absorbed and has a relatively short t1/2 of 3.2 h. 
Piperaquine is also well absorbed after oral administration with a t1/2 of about 228.33 h.
Conclusions: The study showed that FDC of arterolane maleate and PQP effectively cured vivax malaria and attained 
acceptable level of cure up to day 28. Both the groups showed similar safety profile.
Trial Registration Clinical Trial Registry India: CTRI/2011/11/002129
Keywords: Arterolane maleate and piperaquine phosphate, Chloroquine, Plasmodium vivax, Primary efficacy analysis, 
Parasite clearance time, Fever clearance time, Cure rate, Fixed dose combination, Pharmacokinetics
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In a phase III study conducted with FDC of arterolane 
maleate and PQP in an adult population, the efficacy of 
the combination has already been demonstrated against 
falciparum malaria regardless of geographic region, 
patient age, gender, or degree of parasitaemia and has 
been found safe and well tolerated. The drug has already 
been used for the treatment of patients with falciparum 
malaria across the wider population in India for more 
than a year. This phase III study was designed to evalu-
ate efficacy and safety of FDC of arterolane maleate 
150 mg and PQP 750 mg in comparison to chloroquine 
in patients with acute uncomplicated vivax malaria.
Methods
Study site and enrolment
This phase III, open-label, multicentric study was con-
ducted from November 2011 to January 2013 at nine 
clinical trial centres in India. Patients were enrolled at 
the National Institute of Malaria Research and Bensups 
Hospital, New Delhi; Calcutta School of Tropical Medi-
cine, Kolkata; BYL Nair Charitable Hospital and TN 
Medical College Mumbai; Seth GS Medical College and 
KEM hospital, Mumbai; SP Medical College, Bikaner; 
SBKS Medical College and Dhiraj Hospital, Vadodara; 
Kasturba Medical College, Wenlock District Government 
Hospital, Mangalore; Andhra Medical College and King 
George Hospital, Visakhapatnam and Civil Hospital, 
Ahmedabad.
Inclusion and exclusion criteria
Patients with P. vivax mono-infection, aged between 
13 and 65  years, weighing ≥40  kg were included into 
the study after obtaining informed consent/assent, as 
appropriate. Additional inclusion criteria were parasite 
density of >250/µl blood, presence of axillary tempera-
ture ≥37.5 °C or oral temperature ≥38 °C or fever in the 
previous 48 h, willingness and ability of patients to com-
ply with the study protocol, and those residing within a 
reasonable distance of the investigational site. Female 
patients, of child-bearing potential were included if 
they were non-lactating and willing to use contraceptive 
methods during the study period.
Exclusion criteria included mixed Plasmodium infec-
tion; severe malaria; haemoglobin <8  g/dl; history of 
haemolytic anaemia or methaemoglobinaemia; pregnant 
and lactating females; known allergy to artesunate, arte-
misinin-derived products, PQP, chloroquine, primaquine 
or any other related drugs; evidence of gastro-intestinal 
dysfunction that could alter absorption or motility (e.g., 
diarrhoea defined as >3 episodes of watery stools in the 
previous 24  h or patients who have had three episodes 
of vomiting within 24 h prior to screening); use of con-
comitant medications that could induce haemolysis or 
haemolytic anaemia or depressants of myeloid element 
of the bone marrow; any anti-malarial treatment taken 
during 1 month prior to screening; ongoing prophylaxis 
with drugs having anti-malarial activity such as cotri-
moxazole; participation in any other investigational drug 
study of at least 3 months prior to screening; any other 
underlying disease that could compromise the diag-
nosis and the evaluation of the response to the study 
medication (including clinical symptoms of immuno-
suppression, tuberculosis, bacterial infection, cardiac or 
pulmonary disease); electrocardiogram (ECG) abnormal-
ities with clinical significance or relevance that required 
urgent management (these abnormalities included QTc 
interval >450  ms at screening and cardiac conduction 
disorders, with the exception of right bundle branch 
block); evidence of significant renal or hepatic impair-
ment (serum creatinine >1.5 ULN aspartate transaminase 
>2.5 ×  ULN, alanine transaminase >2.5 ×  ULN, serum 
bilirubin  >3  mg/dL); splenectomy conducted earlier as 
confirmed by history or clinical examination; known 
history of human immunodeficiency virus (HIV) infec-
tion or other immunosuppressive disorders; evidence of 
clinically significant cardiovascular, pulmonary, meta-
bolic, gastrointestinal, neurological, or endocrine dis-
eases, malignancy, or other abnormalities (other than 
the indication being studied) that could compromise the 
diagnosis and the evaluation of the response to the study 
medication; history of epilepsy or convulsions; G6PD-
deficient patients; retinal/visual field defects or auditory 
defects and history of psoriasis and porphyria.
Ethical considerations
The study was conducted as per the study protocol that 
was reviewed and approved by the Institutional Ethics 
Committes/Independent Review Boards of the partici-
pating study sites and regulatory authority. This clinical 
study was conducted in accordance with the Good Clini-
cal Practice, applicable regulatory requirements, and 
Declaration of Helsinki. Written informed consent 
was obtained from all patients. In addition, assent was 
obtained from patients who were <18 years of age wher-
ever it was feasible to the extent of patient’s capabilities. 
This study is registered with Clinical Trial Registry India, 
CTRI number CTRI/2011/11/002129.
Study treatments
Patients were assigned to either of the two study treat-
ments in the ratio of 1:1 according to the randomization 
schedule. The randomization schedule was stratified by 
centre in permuted block scheme. Patients were admin-
istered three doses of FDC of arterolane maleate 150 mg 
and PQP 750  mg tablets, and four doses (total of ten 
tablets of 250  mg each) of chloroquine tablets for three 
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consecutive days. If a patient vomited within 30 min after 
receiving any dose of investigational products on any of 
the dosing days, the patient was administered a repeat 
dose. If the patient vomited again within 30  min after 
receiving the repeat dose, the patient was withdrawn 
from the study and given rescue treatment. Re-dosing in 
case of vomiting was allowed only once during the study.
Following the 3  day treatment period, anti-relapse 
medication, primaquine tablets 26.3  mg (equivalent to 
15 mg base) was issued to patients for consuming orally 
over 14 consecutive days (one tablet/day). First dose of 
primaquine phosphate was administered to the patients 
under supervision on day 3 except in patients who were 
discharged on day 2 due to personal or social reasons. 
Compliance to primaquine therapy was confirmed dur-
ing follow-up days.
Clinical and laboratory assessments
The study included a pretreatment period (screening day 
0), treatment period (days 0 to 2) and post-treatment 
period (days 3 to 42). The total duration of patient’s par-
ticipation in the study was at least 42 days following the 
first dose of study medication. Patients were hospitalized 
at the clinical trial site for at least three days (days 0, 1 
and 2); the hospitalization was extended until patients 
were aparasitaemic. Patients were discharged on day 3 
and they returned for follow-up assessments on days 7, 
14, 21, 28, 35, and 42.
At the time of screening, physical examination and 
clinical assessment was carried out, and vital signs (pulse 
rate, respiratory rate and Blood Pressure), height, weight 
and body temperature were measured. Screening assess-
ment also included testing for G6PD deficiency, urine 
pregnancy test, 12-Lead ECG, parasitological and labora-
tory investigations.
Physical examination was carried out on days 0, 1, 2 
and 3 and at follow-up visits on days 21, 28 and 42. Clini-
cal signs and symptoms, body temperature and vital signs 
were assessed during the three-day treatment period and 
at all follow-up visits. The assessments were repeated 
in case the patient reported with fever. Post-dose ECG 
measurements were done on day 2 (between two and 
four hours) after the last dose of either of the investiga-
tional products and if abnormal, ECG was recommended 
to be repeated on subsequent visit or earlier.
Body temperature was recorded at 6  h intervals (or 
adjusted to the closest possible 6 h interval to make the 
schedule consistent with routine care) following the first 
dose of study medication until temperature normal-
ized and remained normal for 24  h, and at every visit 
thereafter.
Blood smears were prepared and parasite counts meas-
ured at screening, predose and at six-hourly intervals 
following the first dose of study medication until two 
consecutive negative smears were obtained, thereafter at 
day 3 and all follow-up visits.
Laboratory parameters (haematology, biochemistry 
and urinalysis) were assessed on the day of discharge, 
days 28, 42 or any unscheduled day when required. Preg-
nancy test was repeated on days 28 and 42.
Any deviations to the study procedures were recorded 
as protocol deviations. Adverse events were reported 
for the time of study medication administration and at 
all follow-up visits. Adverse events reported during the 
study were adequately followed up until resolution/sta-
bilization or until determination that no further follow 
up was deemed necessary. Every effort was made by the 
study staff to follow up adverse events after day 42.
Drug concentration measurements
The concentration of arterolane, piperaquine, chloro-
quine and desethylchloroquine in the plasma samples 
were estimated by LC–MS/MS methods as per US FDA 
Guidance for Industry: Bioanalytical Method Validation, 
May 2001 [17]. Analyses were performed in compliance 
with GLP regulations.
Blood sampling for pharmacokinetic analysis
A total of nineteen, 1.0  mL venous blood samples were 
collected from each enrolled patient who were admin-
istered with FDC of arterolane maleate and PQP and 
twenty, 1.0  mL venous blood samples were collected 
from patients who were administered with chloroquine. 
The sample collection time points for each schedule are 
given below:
Sampling schedule A: (FDC of arterolane maleate and 
PQP)
Day 0: pre-dose, 0.75, 1.5, 3, 8 and 16 h post first dose.
Day 2: pre-dose, 1.5, 3, 4, 5, 6, 12 and 24 h post third 
dose.
Day 14, day 21, day 28, day 35 and day 42 follow-up vis-
its.
Sampling schedule B: (chloroquine)
Day 0: pre-dose, 0.75, 1.5, 3, pre-dose (2nd dose), 10 
and 16 h post first dose.
Day 2: pre-dose, 1.5, 2, 3, 4, 6, 12, and 24 h post fourth 
dose.
Day 14, day 21, day 28, day 35 and day 42 follow-up 
visits.
Bioanalysis of arterolane and piperaquine
A high performance liquid chromatography mass spec-
trometric method for the simultaneous estimation of 
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arterolane and piperaquine in human plasma was vali-
dated as per USFDA guidelines. The method was vali-
dated over a concentration range of 1.15–402.72 ng/mL 
for arterolane and 1.15–403.18  ng/mL for piperaquine. 
Sample clean-up was accomplished by protein precipita-
tion method using methanol. The samples were analysed 
by 4000 Q TRAP MS/MS detector in positive ion mode 
(using a Chromolith SpeedROD RP-18e (50–4.6  mm). 
The method was found to be sensitive, selective, repro-
ducible, accurate and precise over the above-mentioned 
range. Matrix effect was also found to be insignificant and 
the stability of analytes in matrix established successfully.
Bioanalysis of chloroquine and desethyl chloroquine
A high performance liquid chromatography mass spec-
trometric method for the simultaneous estimation of 
chloroquine and desethyl chloroquine in human plasma 
as per USFDA guidelines. The method was validated over 
a concentration range of 2.03–502.57 ng/mL for chloro-
quine and 2.02–501.73  ng/mL for desethyl chloroquine. 
Sample processing was accomplished by liquid–liquid 
extraction using ethyl acetate. The samples were analysed 
by API 4000 MS/MS and 4000 Q TRAP MS/MS detector 
in positive ion mode (using a Chromolith Performance 
RP-18e (100–4.6 mm). The method was found to be sen-
sitive, selective, reproducible, accurate and precise over 
the above-mentioned range. Matrix effect was also found 
to be insignificant and the stability of analytes in matrix 
established successfully.
Pharmacokinetic analysis method
Concentration–time data for arterolane, piperaquine, 
chloroquine and desethylchloroquine were used to 
estimate pharmacokinetic parameters using non-com-
partmental analysis (NCA) in WinNonlin® version 5.3 
software.
Outcomes
The primary efficacy outcome was proportion of apara-
sitaemic and afebrile patients at 72 h. Secondary efficacy 
outcome included cure rate on day 28, parasite clearance 
time (PCT) and fever clearance time (FCT). Cure rate 
is defined as the absence of parasitaemia irrespective of 
axillary/oral temperature without previously meeting any 
of the criteria of treatment failures. PCT is the time in 
hours from the initiation of therapy until the first of two 
successive negative smears for parasite is obtained. FCT 
is the time in hours from the initiation of therapy until 
disappearance of fever for at least 24 h. Safety endpoints 
included incidence of adverse events or clinically signifi-
cant changes in clinical and laboratory parameters, ECG, 
vital signs, or physical examination findings.
Statistical considerations
Considering an anticipated cure rate of 90  % at day 3 
(proportion of aparasitaemic and afebrile patients at 
72 h), 80 % power and non-inferiority margin of 10 %, a 
total of 284 patients were planned to be evaluated in a 
ratio of 1:1 (142 evaluable patients in FDC of arterolane 
maleate and PQP group and 142 evaluable patients in 
chloroquine group). About 316 patients (including drop-
out rate of 10 %) were planned to be enrolled to have 284 
evaluable patients. Data listings and analyses were per-
formed using Statistical Analysis System (SAS®) version 
9.1.3, SAS Institute, Cary, NC, USA.
Descriptive statistics for continuous and ordinal vari-
ables included mean, standard deviation, 95 % confidence 
interval of the mean as well as median, minimum, maxi-
mum values and quartiles. Categorical variables, such as 
cure rate, were summarized using count and percentage. 
Time to event was summarized by number of events, 
median time and quartiles.
Primary efficacy analysis, i.e., proportion of aparasitae-
mic and afebrile patients at 72 h was performed for all eval-
uable (i.e., per protocol population (PP)) and all enrolled 
(i.e., intent to treat population (ITT)] patients. Secondary 
efficacy endpoint analysis [PCT, FCT and cure rate at day 
28) was performed for all enrolled patients. Cure rate at 
day 28 was also computed on all evaluable patients. The 
PP population included all patients who completed a full 
course of study medication with a known efficacy endpoint 
and who did not violate the protocol in a way that could 
affect the efficacy analysis, i.e., the use of prohibited con-
comitant medication, the presence of significant disease or 
co-morbid illness, or major protocol violation.
Efficacy proportions were estimated along with their 
95  % exact binomial confidence interval for each treat-
ment group and compared between the groups using 
Fisher exact test and two-sided 95 % Wilson’s confidence 
interval. Median PCT and FCT was estimated using 
survival analysis method Kaplan–Meier Graph, and 
between group, comparison was made using Log-rank 
test. Patients with early withdrawal or those who could 
not clear parasite or fever at 72 h were censored at day 7 
(168 h), i.e., next follow-up visit. These patients were con-
sidered failures in ITT analysis.
Safety analysis was conducted on safety population, i.e., 
all patients who had received at least one dose of study 
drug. Analysis of adverse events, laboratory data and other 
safety evaluations were performed using summary statis-
tics. Data of adverse events was reported in terms of date 
of onset, intensity or severity, relationship and outcome. 
Intensity or severity of adverse events was defined using 
CTCAE version 3.0 toxicity criteria which identifies five 
grades: mild, moderate, severe, life threatening, and death.
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Results
Patient disposition, demography and other baseline 
characteristics
A total of 317 patients were randomized with 159 
patients receiving FDC of arterolane maleate and PQP 
and 158 patients receiving chloroquine. All patients were 
included in safety analysis. Two-hundred and seven (207) 
patients completed the study, i.e., day 42. The patient 
population was dominated by males 282 (89.0  %). The 
mean age of the patients was 33.5 ± 12.64 years. Average 
height and weight of the patients was 163.6 ±  8.24  cm 
and 58.2  ±  10.25  kg, respectively. Patient demography 
and baseline characteristics are summarized in Table  1 
and patient disposition in Fig. 1.
Efficacy
A total of 286 (90.2 %) patients out of 317 patients were 
evaluable on day 3 (140 patients in FDC of arterolane 
maleate and PQP group and 146 patients in chloroquine 
group). In PP population, all patients (100  %; 140/140) 
Table 1 Demographic and baseline clinical characteristics








 Male 137 (86.2 %) 145 (91.8 %) 282 (89.0 %)
 Female 2 2 (13.8 %) 13 (8.2 %) 35 (11.0 %)
Race
 Asian 159 (100.0 %) 158 (100.0 %) 317 (100.0 %)
Age (years)
 Mean ± std 33.2 ± 11.81 33.7 ± 13.45 33.5 ± 12.64
 Median 32 30 30
 Min, max 13.0, 65.0 15.0, 65.0 13.0, 65.0
Height (cm)
 Mean ± std 163.6 ± 7.83 163.6 ± 8.67 163.6 ± 8.24
 Median 164 164 164
 Min, max 130.0, 179.0 131.0, 182.0 130.0, 182.0
Weight (kg)
 Mean ± std 57.6 ± 8.76 58.8 ± 11.55 58.2 ± 10.25
 Median 57 56.4 57
 Min, max 42.0, 81.0 41.2, 128.9 41.2, 128.9
No. of subjects having P. vivax asexual parasites (/µL) at screening
 Mean ± std 6458.9 ± 11,439.07 5943.6 ± 10,401.49 6202.9 ± 10,921.57
 Median 2704 2880 2750.5
 GM 2749.7 2706.5 2728.2
 Min, max 250.0, 90,049.0 280.0, 80,000.0 250.0, 90,049.0
Body temperature (degree celsius)
 Mean ± std 38.5 ± 0.62 38.5 ± 0.61 38.5 ± 0.61
 Median 38.6 38.6 38.6
 Min, max 36.1, 40.2 36.8, 40.4 36.1, 40.4
Fever >(38.0 degree celsius) 122 (76.7 %) 118 (74.7 %) 240 (75.7 %)
No. of subjects having normal temperature (<37.5 degree celsius) at screening 6 (3.8 %) 3 (1.9 %) 9 (2.8 %)
Hepatomegaly 10 (6.3 %) 12 (7.6 %) 22 (6.9 %)
Splenomegaly 10 (6.3 %) 14 (8.9 %) 24 (7.6 %)
Anemia <30 % at screening 12 (7.55 %) 11 (6.96 %) 23 (7.26 %)
Hematocrit at screening
 Mean ± SD 37.14 ± 5.35 37.75 ± 5.30 37.45 ± 5.33
 Median 37.4 37.75 37.5
 Min, max 19.8, 50 2254.7 19.8, 54.7
G6PD deficiency 0 0 0
P. vivax infections in prior 12 months 9 (5.66 %) 8 (5.03 %) 17 (5.36 %)
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were aparasitaemic and afebrile at 72 h in FDC of arter-
olane maleate and PQP group compared to 99.3  % 
(145/146) patients in chloroquine treatment group, 
(Fisher, p  >  0.9999). Both treatments showed efficacy 
more than 95 % at 72 h, lower 95 % confidence intervals 
were well above 95 % of success rate in both treatments 
(Table 2). In ITT population, a total of 154 (96.9 %) out 
of 159 patients were considered to be aparasitaemic and 
afebrile at 72  h in FDC of arterolane maleate and PQP 
group whereas 156 (98.7  %) out of 158 patients were 
Fig. 1 Patients disposition
Table 2 Proportion of  patients aparasitemic and  afebrile 
at 72 h (intent to treat population)




Success (n,  %) 154 (96.9) 156 (98.7)
95 % CI (92.81, 98.97) (95.50, 99.85)
Wilson 95 % CI
(AM + PQP—Chloroquine)
−1.9 (−5.99, 1.82)
Fisher’s exact p value 0.4479
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considered to be aparasitaemic and afebrile at 72  h in 
chloroquine group (Fisher, p = 0.4479). The difference in 
FDC of arterolane and PQP group was noted in less than 
2 % over the chloroquine arm, the lower 95 % confidence 
limit was well within the prespecified, non-inferiority 
criteria of −10 % [Table 2, Wilson 95 % CI (−5.99, 1.82)].
The secondary variables, day 28 cure rate, PCT and 
FCT were reported as below: in PP population (n = 215; 
104 in FDC of arterolane maleate and PQP group and 
111 in chloroquine group), day 28 cure rates were 100 % 
in both the treatment groups [95 % CI (96.52, 100.0 for 
FDC of arterolane maleate and PQP and 96.73, 100.0 in 
chloroquine group)]. Whereas, the results were compa-
rable in ITT population with a total of 109 (68.6 %, 95 % 
CI 60.72, 75.68) patients out of 159 were considered to be 
cured on day 28 after administration of FDC of arterolane 
maleate and PQP and 115 (72.8 %, 95 % CI 65.14, 79.55) 
patients out of 158 were considered to be cured on day 28 
after receiving chloroquine (Table 3). Three patients had 
reappearance of P. vivax at day 42 in choloroquine group 
but none was seen in the FDC group.
The median PCT was estimated to be 24  h (18.0–
31.0  h) in FDC of arterolane maleate and PQP group 
whereas PCT of 26 h (18.0–36.0 h) was noted in chloro-
quine group (Log-rank, p = 0.2264). Both the study treat-
ments demonstrated identical PCT (Table 4 and Fig. 2).
Table 3 Cure rate at day 28 (intent to treat population)
Cure rate at day 28 in PP population was 100 % and has been referred in details 
in the text




Success 109 (68.6) 115 (72.8)
95 % CI (60.72, 75.68) (65.14, 79.55)
Wilson 95 % CI
(AM + PQP—Chloroquine)
−4.2 (−14.1, 5.77)
Fisher’s exact p Value 0.4596
Table 4 Parasite clearance time (PCT) (intent to treat pop-
ulation)
Kaplan–Meier graph, Fig. 2
Statistical summary AM + PQP Chloroquine
Time to parasite clearance (hours)
Quartile estimate (95 % confidence interval)
25 % 18.0 (NE, NE) 18.0 (16.0, 18.0)
50 % (median) 24.0 (21.0, 24.0) 26.0 (24.0, 30.0)
75 % 31.0 (30.0, 36.0) 36.0 (30.0, 42.0)
Mean 25.6 28.3
Log-rank test p value 0.2264
Fig. 2 Time to parasite clearance (PCT) Kaplan–Meier method
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Median FCT in ITT Population was 24  h in both the 
treatment groups (Log-rank, p = 0.7750, 12–36 h in FDC 
of arterolane maleate and PQP group and 12–42  h in 
chloroquine group) (Table 5 and Fig. 3).
Pharmacokinetic results
Pharmacokinetic parameters were evaluated in 89 
patients in FDC of arterolane maleate and PQP and 80 
patients in chloroquine group.
Arterolane, quantifiable concentration levels were 
observed up to day 2, which was consistent with a short 
half-life for this drug. This corroborates with the findings 
in clinical studies conducted earlier on this combination 
product. Piperaquine concentrations however, could be 
quantified until 42  days. This is also expected based on 
the long terminal half-life of piperaquine. Similarly, chlo-
roquine and desethyl chloroquine, quantifiable concen-
tration levels were observed up to day 42, indicating a 
long half-life for this drug.
A mean Cmax of 60.26  ng/mL (ranging from 25.11 to 
161.81  ng/ml) and a mean t1/2 of 3.20  h (ranging from 
0.48 to 8.74 h) was observed for arterolane. Similarly, the 
mean Cmax and mean t1/2 for piperaquine were 317.82 ng/
mL (ranging from 89.13 to 817.14) and 228.33 h (ranging 
from 10.26 to 757.03 h), respectively.
Chloroquine showed a mean Cmax of 464.17  ng/mL 
(ranging from 181.57 to 2467.27 ng/mL) and mean t1/2 of 
172.47 h (ranging from 12.92 to 757.32 h), while deseth-
ylchloroquine exhibited a mean Cmax of 146.33  ng/mL 
(ranging from 51.70 to 790.32 ng/mL) and a mean t1/2 of 
209.06 h (ranging from 17.32 to 525.77 h).
Mean pharmacokinetic parameters along with descrip-
tive statistics for FDC of arterolane maleate and PQP and 
chloroquine are summarized in Table 6, respectively.
The relationship of PCT versus Cmax of arterolane and 
chloroquine is shown in Figs.  4 and 5, respectively. The 
distribution of PCT appears to be fairly uniform. This 
Table 5 Fever clearance time (FCT) (intent to treat popula-
tion)
Kaplan–Meier graph, Fig. 3
Statistical summary AM + PQP Chloroquine
Time to fever clearance (hours)
Quartile estimate (95 % confidence interval)
25 % 12.0 (12.0, 18.0) 12.0 (6.0, 12.0)
50 % (median) 24.0 (18.0, 30.0) 24.0 (18.0, 30.0)
75 % 36.0 (36.0, 42.0) 42.0 (36.0, 42.0)
Mean 25.2 25.4
Log-rank test p value 0.7750
Fig. 3 Time to fever clearance (FCT) Kaplan–Meier method
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indicates that, among the patients evaluated, there is no 
potential relationship of PCT with Cmax of arterolane and 
chloroquine. Exposure (AUC last) of arterolane and chlo-
roquine was also plotted against PCT (hours). From the 
plot, it appears that arterolane exposure levels (AUC last) 
of less than ~2.5 µg.h/ml (Fig. 6) and chloroquine expo-
sure levels (AUC last) of less than ~80 µg.h/ml (Fig. 7) are 
potentially sufficient to result in a PCT ranging from 12 
to 60 h and 12 to 73 h, respectively.
Safety
Incidence of adverse events was 82.4 % (131/159) in FDC 
of arterolane maleate and PQP and 85.4  % (135/158) 
in chloroquine group (Additional file  1: Table S1). The 
majority of adverse events were related to laboratory 
parameters in both the study groups. Overall, most of the 
adverse events were mild to moderate in intensity. The 
commonly reported clinical adverse events in FDC of 
arterolane maleate and PQP versus chloroquine groups 
were vomiting (5.0 vs 5.1 %), headache (1.3 vs 3.2 %) and 
prolonged QT interval (1.9 vs 3.2  %). Four patients in 
the FDC of arterolane maleate and PQP group had seri-
ous adverse events: enteric fever, fever on day 5 (patient 
was negative for malarial parasite), dehydration and 
acute glomerulonephritis; all these events were mild to 
moderate in intensity and resolved without any seque-
lae. As these patients were hospitalized, the events were 
considered to be serious. All the events were judged by 
the investigator as not related to the study medication, 
except acute glomerulonephritis, which was judged to be 
related to the study medication. The diagnosis of acute 
glomerulonephritis was based on clinical judgement and 
no biopsy was performed. There were no deaths reported 
during the course of the study.
QTc interval >500  ms was not reported in any of the 
patients. However, a change in QTc interval of >60  ms 
over baseline was observed in three patients (1.9  %) 
from FDC of arterolane maleate and PQP group and five 
patients (3.2 %) from chloroquine group. The mean QTc 
interval after Fridericia’s correction was 395.3  ms on 
day 0 and 401.1  ms on day 2 after treatment with FDC 
of arterolane maleate and PQP, whereas, the mean QTc 
interval after Fridericia’s correction was 395.7 ms on day 
0 and 406.3 ms on day 2 after treatment with chloroquine 
(between group comparison, t-test, p = 0.0920). All events 
of prolongation of QTc interval were judged by the inves-
tigators to be mild to moderate in severity. No event was 
judged to be clinically significant. There were no instances 
of Torsade de Pointes, sudden death, ventricular tachycar-
dia, ventricular fibrillation and flutter, syncope or seizure 
in any of the patients which could be identified as a direct 
outcome of significant prolongation of QTc interval.
Amongst the laboratory parameters, concentra-
tion of haemoglobin, platelet count, reticulocyte count, 
Table 6 Mean pharmacokinetic parameters of arterolane, piperaquine, chloroquine and desethylchloroquine
Analyte Parameters Cmax (ng/mL) AUClast (ng*h/mL) AUC48–72 (ng*h/mL) t1/2 (h)
Arterolane N 89 89 83 48
Mean 60.26 1250.09 377.46 3.20
Minimum 25.11 178.29 15.24 0.48
Maximum 161.81 3744.98 1100.65 8.74
% CV 42.23 53.90 62.65 43.06
Piperaquine N 89 89 84 82
Mean 317.82 40,424.88 4449.79 228.33
Minimum 89.13 3548.46 1546.86 10.26
Maximum 817.14 192,153.39 13,368.70 757.03
% CV 46.45 72.65 46.03 54.49
Chloroquine N 80 80 78 76
Mean 464.17 68,969.77 7474.60 172.47
Minimum 181.57 10,005.45 3222.40 12.92
Maximum 2467.27 231,867.11 15,445.88 757.32
% CV 60.74 48.80 30.15 61.00
Desethylchloroquine N 78 78 78 78
Mean 146.33 28,715.98 2625.74 209.06
Minimum 51.70 2711.74 996.96 17.32
Maximum 790.32 109,362.90 5931.30 525.77
% CV 70.33 60.28 41.56 47.29
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eosinophil count, serum potassium and sodium, ALT and 
blood glucose values reported on day 0, 3, 28 and 42 were 
evaluated. Mean concentration/counts were similar after 
the treatment with arterolane maleate and PQP or chlo-
roquine at these time points.
Discussion
Plasmodium vivax is the dominant species of malaria 
in many areas outside Africa [18]. Due to emergence of 
high-grade, multidrug resistance in both P. falciparum 
and P. vivax to chloroquine, amodiaquine and sulfadox-
ine-pyrimethamine, only limited treatment options are 
available [19].
In this study, 100  % of patients treated with FDC of 
arterolane maleate and PQP were aparasitaemic and afe-
brile at day 3 compared to 99.3 % of patients on chloro-
quine treatment. The efficacy rate of more than 95 % was 
reported at 72 h in the both treatment groups.
It is recommended by WHO that in areas where ACT, 
except artesunate plus sulfadoxine-pyrimethamine 
which is not effective against P. vivax in many places, has 
been adopted as the first-line treatment for falciparum 
malaria, may also be used for vivax malaria. Also, in areas 
with chloroquine-resistant P. vivax, ACT (particularly the 
combination having partner medicines with long-half-
lives) is recommended for the treatment of vivax malaria 
[1]. The artemisinin derivatives are the most rapidly act-
ing and potent among anti-malarial medicines [20].
Arterolane maleate is the short-acting component in 
the FDC of arterolane maleate and PQP, which contrib-
utes significantly in achieving early parasite clearance. 
The time to parasite clearance and fever clearance seen 
with FDC of arterolane maleate and PQP in this study 
are on expected lines since the clinical efficacy of the 
artemisinin derivatives is characterized by an almost 
immediate onset of activity and rapid reduction of para-
sitaemia, with complete clearance in most cases within 
48 h [21]. Median time to parasite clearance was 24.0 h in 
FDC of arterolane maleate and PQP group and 26.0 h in 
chloroquine group. Median FCT was 24.0 h in both the 
treatment groups.
Day 28 cure rates were 100 % in PP population in both 
the treatment groups. In ITT population analysis cure 
rates were reported to be close to 70 % because most of 
the patients were lost to follow-up, which was consid-
ered as failure in the statistical analysis. The possible rea-
son for loss of patients to follow up was migration as the 
study was conducted in urban settings.
Effectiveness of FDC of arterolane maleate and PQP 
for P. vivax infections would establish a common treat-
ment for both circulating Plasmodium species, P. falcipa-
rum and P. vivax. FDC of arterolane maleate and PQP is 
highly effective against P. falciparum based on previously 
conducted studies [22, 23]. Reports from Thailand and 
Indonesia detected up to 23 % of P. falciparum infections 
being wrongly diagnosed as P. vivax, leading to inappro-
priate treatment with chloroquine. Treating P. falciparum 
with FDC of arterolane maleate and PQP and primaquine 
would have the advantage of also treating potential 
Fig. 4 PCT as a function of arterolane Cmax
Fig. 5 PCT as a function of chloroquine Cmax
Fig. 6 PCT as a function of arterolane exposure (AUC last)
Fig. 7 PCT as a function of chloroquine (AUC last)
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dormant P. vivax hypnozoites, which are thought to 
become activated due to P. falciparum infections, thereby 
explaining the high number of vivax infections after P. 
falciparum treatment [24].
In this study, no deaths were reported and all the four 
serious adverse events were mild to moderate in intensity 
and recovered without sequelae. As these patients were 
hospitalized, the adverse events were considered to be 
serious in nature. Overall, the incidence of adverse events 
was similar to incidence reported in patients treated with 
PQP combinations with DHA in various other studies 
[12, 13].
The proportion of patients with QTc prolongation of 
>60  ms from baseline in patients treated with FDC of 
arterolane maleate and PQP were 1.9  % compared to 
3.2  % in chloroquine group. Evaluation of QT interval 
changes is problematic in malaria because of systematic 
differences between the acute febrile admission before 
anti-malarial drugs are given and early convalescence. 
At presentation, patients are usually anxious, fasting 
and febrile with increased autonomic tone and a raised 
heart rate. This is in contrast to the relaxed, fed, supine, 
afebrile state 3 days later when most anti-malarial treat-
ments finish and anti-malarial concentrations are at the 
highest. It has been argued that this systematic reduction 
in sympathetic activity with recovery leads to a consist-
ent increase in the QT interval which has been mistak-
enly ascribed to anti-malarial drug effects. It has been 
reported in literature that QTc prolongation of >60 ms is 
within the bounds of normal daily variation in the QTc 
(up to 75–100 ms) [25, 26].
Amongst the laboratory parameters, concentration of 
haemoglobin, platelet count, reticulocyte count, eosino-
phil count, serum potassium and sodium, ALT and blood 
glucose were evaluated. Mean concentration/counts 
reported during laboratory assessments were similar 
after treatment with FDC of arterolane maleate and PQP 
or chloroquine. By proportion, the incidence of increased 
transaminase (ALT and AST) was similar in both the 
treatment groups. This observation combined with the 
fact that the FDC of arterolane maleate and PQP is only 
administered once daily for 3  days suggests that there 
is a very low risk of liver injury with FDC of arterolane 
maleate and PQP.
Pharmacokinetic results through non-compartmental 
analysis indicate that the mean rate and extent of absorp-
tion for arterolane maleate and PQP were apparently sim-
ilar to those observed in patients treated for falciparum 
malaria. Similarly, the Cmax and AUC for chloroquine and 
desethylchloroquine corroborated well with literature-
based information [27]. PCT for patients treated with 
the FDC of arterolane maleate and PQP seems numeri-
cally lower than that for the chloroquine. Exposures for 
chloroquine were higher as compared to piperaquine 
exposures.
Arterolane (a completely synthetic, ozonide anti-malar-
ial based upon the 1,2,4-trioxolane pharmacophore) in 
combination with PQP exhibits a rapid onset of action, 
potent activity against all erythrocytic stages of P. vivax. 
Once-a-day treatment with three doses of FDC of arter-
olane maleate and PQP efficacy and safety profile simi-
lar to chloroquine and no reappearance of vivax malaria 
noted until day 42 makes this combination a promising 
candidate, which could lead to better treatment compli-
ance and patient adherence.
Conclusion
The findings from this study show that FDC of arterolane 
maleate and PQP effectively cure vivax malaria and attain 
acceptable level of cure up to day 28. Both the groups 
have shown similar safety profile.
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